

Recombinant Human EDIL3 (C-6His)

Catalog # EPT076

Expression Host Human Cells

DESCRIPTION Recombinant Human EGF-Like Repeat And Discoidin

I-Like Domain-Containing Protein 3 is produced by

our Mammalian expression system and the target

gene encoding Asp24-Glu480 is expressed with a 6His

tag at the C-terminus.

Accession O43854-1

Synonyms EGF-Like Repeats and Discoidin I-Like Domains 3;

EDIL3

Mol Mass 53.09 KDa

AP Mol Mass 55-65 KDa, reducing conditions

Purity Greater than 95% as determined by reducing

SDS-PAGE.

Endotoxin Less than 0.1 ng/μg (1 EU/μg) as determined by LAL

test.

FORMULATION Supplied as a 0.2 μ m filtered solution of 20mM

Tris-HCl, 300mM NaCl, pH8.0.



www.elkbiotech.com



RECONSTITUTION

SHIPPING

The product is shipped on dry ice/polar packs.

Upon receipt, store it immediately at the temperature

listed below.

STORAGE

Store at \leq -70°C, stable for 6 months after receipt.

Store at \leq -70 °C, stable for 3 months under sterile

conditions after opening.

Please minimize freeze-thaw cycles.

BACKGROUND

Discoidin EGF-Like Repeat and I-Like Domain-Containing Protein 3 (EDIL3) is a 52 kDa extracellular matrix protein that is expressed by endothelial tissues during embryonic vascular development. EDIL3 becomes quiescent at the time of birth, and is no longer expressed in normal adult tissues. EDIL3 has been found to be re-expressed in a number of human tumors as well as in ischemic muscles and ischemic brain tissue, which may play an important role in adult angiogenesis. EDIL3 promotes adherence and migration of endothelial cells, and acts an endothelial cell survival agent through as upregulation of Bcl-2 expression. EDIL3 has also been shown to be an endogenous inhibitor of inflammatory





cell recruitment by interfering with the integrin LFA-1-dependent leukocyte-endothelial adhesion. Human EDIL3 is synthesized as a precursor with a 16 amino acid signal sequence and a 464 amino acid mature chain.

kDa	MK	R
120 90 60		-
40		
30		
20	-	
14		

SDS-PAGE

